Recce Pharmaceuticals (RCE) News Today → Invest in the 'Trojan Horse' of Alzheimer's Treatment (From Behind the Markets) (Ad) Free RCE Stock Alerts Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13, 2024 | finance.yahoo.comRecce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot StudyMay 8, 2024 | finance.yahoo.comRecce Pharmaceuticals Granted New Patent in China for RECCE® Anti-InfectivesMay 7, 2024 | au.investing.comRecce Pharmaceuticals granted China patent for RECCE® Anti-InfectivesMay 7, 2024 | msn.comASX Health Stocks: Recce scores patent win in China for its infection drugsApril 30, 2024 | finance.yahoo.comRecce Pharmaceuticals Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and UrosepsisApril 17, 2024 | finance.yahoo.comRecce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)April 10, 2024 | finance.yahoo.comRecce Pharmaceuticals Provides Business UpdateApril 9, 2024 | finance.yahoo.comRecce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024April 4, 2024 | seekingalpha.comRecce pharmaceuticals granted new patent in Israel for anti-infectivesApril 4, 2024 | finance.yahoo.comRecce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-InfectivesMarch 22, 2024 | finance.yahoo.comRecce Pharmaceuticals Announces RECCE® Trademark Registered in Canada, Strengthening Global IP PortfolioMarch 19, 2024 | msn.comRecce hits milestone in Phase I/II trial for UTIs and urosepsisMarch 19, 2024 | finance.yahoo.comRecce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and UrosepsisMarch 18, 2024 | proactiveinvestors.com.auRecce Pharmaceuticals hits major milestone in R327 clinical trial for UTI/urosepsisMarch 18, 2024 | finance.yahoo.comPleasing Signs As A Number Of Insiders Buy Recce Pharmaceuticals StockMarch 14, 2024 | finance.yahoo.comRecce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and UrosepsisMarch 13, 2024 | finance.yahoo.comRecce Pharmaceuticals to Present at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual MeetingMarch 12, 2024 | finance.yahoo.comRecce Pharmaceuticals Receives AUD $11.17 Million Research and Development (R&D) AdvanceFebruary 29, 2024 | finance.yahoo.comRecce Pharmaceuticals Continues Strategic Partnership with Murdoch Children’s Research InstituteFebruary 27, 2024 | finance.yahoo.comRecce Pharmaceuticals Announces Expansion of Phase I/II Trial of RECCE® 327 for the Treatment of Diabetic Foot InfectionsFebruary 9, 2024 | au.finance.yahoo.comRecce Pharmaceuticals Ltd (RCE.AX)February 7, 2024 | finance.yahoo.comRecce Pharmaceuticals Establishes Strategic Partnership in South-East Asia to Accelerate Clinical ProgramFebruary 6, 2024 | afr.comRecce Pharmaceuticals LtdJanuary 14, 2024 | finance.yahoo.comThose who invested in Recce Pharmaceuticals (ASX:RCE) five years ago are up 247%December 19, 2023 | finance.yahoo.comRecce Pharmaceuticals Awarded AusIndustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development ProgramDecember 18, 2023 | finance.yahoo.comRecce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 Against GonorrheaDecember 17, 2023 | au.investing.comRecce Pharmaceuticals awarded A$11 million Advanced Overseas Finding for anti-viral R&D costsDecember 14, 2023 | au.investing.comRecce Pharmaceuticals awarded $43.7 million Advanced Overseas Finding for synthetic anti-infective development programDecember 13, 2023 | au.investing.comRecce Pharmaceuticals achieves strong anti-bacterial effect against deadly Neisseria gonorrhoeae pathogen in animal modelNovember 27, 2023 | finance.yahoo.comRecce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-InfectivesNovember 22, 2023 | proactiveinvestors.comRecce Pharmaceuticals secures Canadian Patent for anti-infectivesNovember 9, 2023 | finance.yahoo.comRecce Pharmaceuticals Completes Dosing First Subjects at 15-Minute Infusion Rate in a Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and UrosepsisNovember 1, 2023 | finance.yahoo.comIt's Unlikely That The CEO Of Recce Pharmaceuticals Ltd (ASX:RCE) Will See A Huge Pay Rise This YearOctober 31, 2023 | proactiveinvestors.com.auRecce Pharmaceuticals presents at Ord Minnett Healthcare ForumOctober 25, 2023 | finance.yahoo.comRecce Pharmaceuticals Announces Safety Committee Approves Faster Infusion Rate in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and UrosepsisOctober 24, 2023 | proactiveinvestors.com.auRecce Pharmaceuticals welcomes safety committee approval of...Recce Pharmaceuticals welcomes safety committee approval of faster...October 23, 2023 | msn.comASX Health Stocks: Recce moves forward in Phase 1/2 study; EMV unveils Gen 2 helmet scanner for ambulanceOctober 11, 2023 | finance.yahoo.comRecce Pharma says commercial potential of its anti-infectives is gaining recognitionOctober 5, 2023 | proactiveinvestors.comRecce Pharmaceuticals raises further funds to progress trials from entitlement shortfallOctober 3, 2023 | finance.yahoo.comRecce Pharmaceuticals Announces Results of Entitlement OfferSeptember 28, 2023 | msn.comRecce completes dosing of healthy subjects in UTI therapy trialSeptember 26, 2023 | finance.yahoo.comRecce Pharmaceuticals Completes Dosing in Phase I/II Clinical Trial of RECCE® 327 for Urinary Tract InfectionsSeptember 22, 2023 | proactiveinvestors.comRecce Pharmaceuticals demonstrates R327 safety profile at faster infusion rateSeptember 13, 2023 | finance.yahoo.comRecce Pharmaceuticals Secures $8M Placement and Launches $3M Entitlement Offer to ShareholdersSeptember 11, 2023 | fool.com.auWhy is the Recce Pharmaceuticals share price collapsing 26% today?September 11, 2023 | proactiveinvestors.com.auRecce Pharmaceuticals secures $8 million in placement, launches $3 million entitlement offerSeptember 1, 2023 | finance.yahoo.comRecce Pharmaceuticals Provides Additional Positive Update on Patients Treated Under “Special Access Scheme”September 1, 2023 | proactiveinvestors.comRecce Pharmaceuticals makes strides with R327G drug in multiple antibiotic-resistant infection casesAugust 29, 2023 | finance.yahoo.comRecce Pharmaceuticals Announces Safety Committee Approves Next Dose of RECCE® 327 at 3,000mg in Phase I/II UTI/Urosepsis Rapid Infusion Clinical TrialAugust 28, 2023 | msn.comRecce receives approval for next cohort dosing in UTI therapy trial Get Recce Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RCE and its competitors with MarketBeat's FREE daily newsletter. Email Address 348 million Americans lives to END as we know it? (Ad)348 million American lives are about to change FOREVER.... Because thanks to one shocking A.I. development I'm revealing for the first time today... To see my free research, simply click here now. RCE Media Mentions By Week RCE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RCE News Sentiment▼0.880.54▲Average Medical News Sentiment RCE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RCE Articles This Week▼11▲RCE Articles Average Week Get Recce Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RCE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Algernon Pharmaceuticals News Today ALK-Abelló A/S News Today Alpha Tau Medical News Today Arno Therapeutics News Today Artelo Biosciences News Today Ascletis Pharma News Today Awakn Life Sciences News Today AXIM Biotechnologies News Today BerGenBio ASA News Today BriaCell Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ASX:RCE) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsObama’s Forever Term [exposed]Porter & CompanyGold Set to EXPLODE!Gold Safe ExchangeThe 1,000X Crypto PlaybookTrue Market InsidersUrgent Nvidia WarningAltimetryCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressWhy Is Gold On a MASSIVE rally? Huge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recce Pharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.